Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 22 March 2024, including: another big deal in radiopharmaceuticals; BioNTech SE’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "AstraZeneca Pays $2bn To Keep Up With The Joneses" - Scrip, 19 Mar, 2024.)
(Also see "BioNTech Is Aggressively Advancing ADCs" - Scrip, 20 Mar, 2024.)
(Also see "China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes" - Scrip, 19 Mar, 2024.)
(Also see "Bangers In MASH: How Rezdiffra's Rivals Stack Up" - Scrip, 15 Mar, 2024.)
(Also see "Lilly, BMS, Microsoft On GenAI’s Machine-First Approach Success, Cell Therapy Use, Regulation" - Scrip, 19 Mar, 2024.)